| Pharmaceutical Information |
| Drug Name |
Moxonidine |
| Drug ID |
BADD_D01503 |
| Description |
Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. As well, moxonidine has been shown to present blood pressure-independent beneficial effects on insulin resistance syndrome. |
| Indications and Usage |
For the treatment of mild to moderate essential or primary hypertension [L1025]. Effective as most first-line antihypertensives when used as monotherapy [A27137]. |
| Marketing Status |
approved; investigational |
| ATC Code |
C02AC05 |
| DrugBank ID |
DB09242
|
| KEGG ID |
D05087
|
| MeSH ID |
C043482
|
| PubChem ID |
4810
|
| TTD Drug ID |
D0E9PK
|
| NDC Product Code |
Not Available |
| UNII |
CC6X0L40GW
|
| Synonyms |
moxonidine | 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine | moxonidin | Cynt | Physiotens | Moxon | Normatens | BE 5895 | BE-5895 |
|
| Chemical Information |
| Molecular Formula |
C9H12ClN5O |
| CAS Registry Number |
75438-57-2 |
| SMILES |
CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
